Picture Berlin Partner Join Cluster HealthCapital Berlin Brandenburg 650x100px

Document › Details

MolMed S.p.A.. (3/9/20). "Press Release: The Board of Directors Approved the 2019 Full Year Financial Results". Milan.

	Organisation	MolMed S.p.A. (MLMD.MI)
	Group	Asahi Glass (AGC) (Group)
	Organisation 2	Autolus Therapeutics Ltd.
	Today	Autolus Therapeutics plc (Nasdaq: AUTL)
	Group	Autolus Therapeutics plc (Nasdaq: AUTL)
	Product	contract manufacturing (biologicals)
	Product 2	Zalmoxis®
	Person	Palmisano, Riccardo (InnovaVector 202210– before MolMed 201606 CEO)
	Person 2	Incerti, Carlo (Forbion 201901– Operating Partner before Sanofi Genzyme + Genzyme + Biofil Srl)

Original document
accessed by [iito] on 2020-03-17

Record changed: 2023-06-05

Picture Consultech GmbH Secure Funding with RnD Grants 650x200px

More documents for Asahi Glass (AGC) (Group)

[1] AGC Biologics. (8/7/24). "Press Release: NEC Bio Therapeutics and AGC Biologics Announce Collaboration to Manufacture Personalized Cancer Vaccines"....
[2] AGC Biologics. (9/13/21). "Press Release: AGC Biologics Expands pDNA and mRNA Manufacturing Capacity at Heidelberg Facility". Heidelberg....
[3] AGC Biologics. (8/20/21). "Press Release: AGC Biologics Announces the Groundbreaking of its New Facility at its Copenhagen, Denmark Site". Copenhagen....
[4] MolMed S.p.A.. (4/14/20). "Press Release: MolMed: the Board of Directors, Based on the Scientific Evidence from the Experiments on Early-stage Pre-clinical Products, Decided to Suspend the Investments in These Projects". Milan....
[5] MolMed S.p.A. (at the request of AGC Inc.). (4/2/20). "Press Release: Offer Document Filed with Consob. Voluntary Public Tender Offer Launched by AGC Inc. on All the Ordinary Shares of MolMed S.p.A. [Not for release where violation of laws or regulations...
[6] AGC Inc.. (3/17/20). "Press Release: AGC Decides to Launch Voluntary Tender Offer for Shares of MolMed"....
[7] MolMed S.p.A.. (3/6/20). "Press Release: MolMed Signs a Multi-year Agreement and Announces the Beginning of a New Collaboration in the Field of T Cell Therapies". Milan....
[8] MolMed S.p.A.. (12/18/19). "Press Release: Italy – the EIB Supports MolMed Investment in Research, Development and Manufacturing for Cancer and Rare Diseases Innovative Treatments". Oxford....
[9] MolMed S.p.A.. (10/10/19). "Press Release: MolMed Informs on Its Decision to Withdraw the Conditional Marketing Authorization of Zalmoxis". Milan....
[10] MolMed S.p.A.. (3/13/19). "Press Release: Partnership in the Field of Rare Genetic Diseases with Rocket Pharma Extended to Three New Therapeutic Indications". Milan....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]